UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2228-5
Program Prior Authorization/Medical Necessity
Medication Apokyn® (apomorphine) injection
P&T Approval Date 12/2020, 12/2021, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Apokyn is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of
hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off”
episodes) associated with advanced Parkinson’s disease.
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Apokyn will be approved based on all of the following criteria:
a. Diagnosis of Parkinson’s disease
-AND-
b. Apokyn will be used as intermittent treatment for OFF episodes
-AND-
c. Prescribed by or in consultation with a neurologist or specialist in the treatment of
Parkinson’s disease
-AND-
d. Patient is currently on a stable dose of a carbidopa/levodopa-containing medication
and will continue receiving treatment with a carbidopa/levodopa-containing
medication while on therapy
-AND-
e. Patient continues to experience ≥ 2 hours of OFF time per day despite optimal
management of carbidopa-levodopa therapy including both of the following:
(1) Taking carbidopa/levodopa on an empty stomach or at least one half-hour or
more before or one hour after a meal or avoidance of high protein diet
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Dose and dosing interval optimization
-AND-
f. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease
therapy from the following adjunctive pharmacotherapy classes (trial must be from
two different classes):
(1) Dopamine agonists (e.g., pramipexole, ropinirole)
(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)
-AND-
g. History of failure, contraindication, or intolerance to Inbrija (levodopa) inhalation
powder
Authorization will be issued for 12 months.
B. Reauthorization
1. Apokyn will be approved based on the following criterion:
a. Documentation of positive clinical response to Apokyn therapy
-AND-
b. Patient will continue to receive treatment with a carbidopa/levodopa-containing
medication
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Apokyn [package insert]. Rockville, MD: MDD US Operations; June 2022.
2. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's Disease:
Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019;33(9):905-918.
© 2025 UnitedHealthcare Services, Inc.
2
3. Liang, TW, Tarsy D. UpToDate. Medical management of motor fluctuations and
dyskinesia in Parkinson’s disease.2025 Apr 15. Accessed May 5, 2025.
4. Olanow, CW et al. Apomorphine sublingual film for off episodes in Parkinson’s disease:
a randomized, double-blind, placebo-controlled phase 3 study. The Lancet Neurology.
2020; 19(2): 135-144.
5. Paik J. Levodopa Inhalation Powder: A Review in Parkinson's Disease. Drugs.
2020;80(8):821-828.
Program Prior Authorization/Medical Necessity – Apokyn (apomorphine)
injection
Change Control
12/2020 New program.
12/2021 Annual review with no changes to clinical criteria. Updated references.
6/2023 Annual review with no changes to clinical criteria. Updated references.
6/2024 Annual review. Updated initial authorization duration to 12 months.
Updated references.
6/2025 Annual review. Removed requirement to step through discontinued
product Kynmobi. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3